Table 1 Characteristics of included studies
Study, Year [Ref] | Trial | Phase of study | Atezolizumab + Chemo (Intervention) (n) | Placebo + Chemo (Control) (n) | PD-L1 positive cases (n) | Mean age (range) | Dose of Atezolizumab | Follow-up duration (months) |
|---|---|---|---|---|---|---|---|---|
Schmid 2018 [14] | NCT02425891 | II | 451 | 451 | 368 | 55 (20-82) | 840 mg, IV on days 1 and 15 | 33 |
Schmid 2020 ([5] | NCT02425891 | III | 451 | 451 | 369 | 55 (46-64) | 840 mg, IV on days 1 and 15 | 42 |
Iwata 2019 [15] | NCT02425891 | III | 34 | 31 | 25 | 57 (31-82) | 840 mg, IV on days 1 and 15 | 24 |
Mittendorf 2020 [16] | NCT03197935 | III | 165 | 168 | 154 | 51 (22-76) | 840 mg, IV on days 1 and 15 | 24 |
Miles 2021 [17] | NCT03125902 | III | 431 | 220 | 292 | 54 (22-85) | 840 mg, IV on days 1 and 15 | 24 |
Brufsky 2021 [18] | NCT02322814 | II | 31 | 47 | 22 | 51 (20-75) | 840 mg, IV on days 1 and 15 | 24 |